Key market players are broadening their product range in developed markets like the U.S to demonstrate the impact of meningococcal vaccines in infants and meningococcal carriage in adolescents
The outbreak of meningococcal meningitis is a severe public health concern and while effective and affordable treatment options are available in the global market, the disease has been found to induce a high rate of mortality and create long-term neurological defects in infants and young children. 50% of bacterial meningitis cases are found in children below five years of age.
The next age group susceptible to the disease is the 15 – 19 years category. Considering the predominant adverse impact of meningococcal meningitis on the young population, top companies like GlaxoSmithKline are working on expanding their product line – including the addition of new formulations – to cater to this demographic.
Increasing adoption rate among the younger population to be witnessed in the coming years
Growing incidence of meningococcal meningitis among young children and adolescents has prompted the inclusion of meningococcal vaccines in national immunisation programmes by the governments of various countries. Demand for meningococcal vaccines for infants surpasses other age groups.
Very recently, a study evaluating the safety and efficacy of a new meningococcal vaccine in adolescents and children indicated a satisfactory short-term safety profile with enhanced levels of immunogenicity. It was also observed that individuals who were administered this vaccine developed immunity levels 9-13 times more than those individuals who were administered regular meningococcal vaccines.
With the outbreak of meningitis threatening the lives of countless young people all over the world, manufacturers are introducing newer molecule formulations and pipeline products in the global market. This is boosting the growth in demand for the various meningococcal vaccines currently being administered across hospitals, clinics, and other global medical facilities.
Lack of awareness of the harmful effects of meningitis on toddlers and young children is challenging growth in adoption of vaccination programmes
Studies indicate that parents of infants and young children are unaware of the disease pathogenesis of meningococcal meningitis and hence do not understand the importance of government initiated meningococcal vaccination programmes. This has eventually led to low adoption of meningococcal vaccines especially in toddlers and children. Consider these statistics:
- Only 1 in 5 parents (about 21%) are aware of the most common manner in which children contract meningococcal disease
- More than half (about 54%) of the parents are not aware that there are different strains of meningococcal bacteria that cause meningococcal meningitis
- Over half (about 52%) of the parents do not know what specific vaccines are included in the immunisation schedule defined by the government in their country of residence
- 7 out of 10 parents (about 69%) are not clear about the extent of damage caused by meningococcal meningitis
This awareness gap is the main factor responsible for low demand for meningococcal vaccines and this is expected to have a negative impact on revenue growth of the global meningococcal vaccines market. There is a need to initiate community awareness of the disease and the importance of administering prescribed vaccines so as to curb the proliferation of meningococcal meningitis at the global level.
This activity can be initiated by government and healthcare organisations in collaboration with hospitals and clinics to educate parents and create the necessary awareness to encourage the adoption of meningococcal vaccines.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
The global meningococcal vaccines market has been segmented on the basis of:
- Product Type
- Age Group
- Distribution Channel
The report analyses the market based on regions and presents a comprehensive forecast in terms of value (US$ Mn) for the next 10 years. Regions covered in the report include:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan (APEJ)
- The Middle East and Africa (MEA)
The next section of report analyses the market based on product types and presents the forecast in terms of value for the next 10 years. Meningococcal vaccine product types covered in the report include:
- Polysaccharide Vaccines
- Conjugate Vaccines
The next section of the report analyses the market based on age group and provides forecast in terms of value for the next 10 years. Based on age groups, the global market has been segmented in to
- Adolescents & Young Adults
The next section of the report analyses the market based on distribution channel for meningococcal vaccine products and provides forecast in terms of value for the next 10 years. Distribution channels covered in this report are:
- Community Clinics
- Public Health Agencies
- Others (hospital pharmacy, private market etc.)